Holen Sie sich die Stockscreener-App
22.29
2.19%
-0.50
Handel nachbörslich:
22.31
0.02
+0.09%
Schlusskurs vom Vortag:
$22.79
Offen:
$22.8
24-Stunden-Volumen:
663.06K
Relative Volume:
0.40
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.85M
KGV:
-10.09
EPS:
-2.21
Netto-Cashflow:
$-106.82M
1W Leistung:
-3.92%
1M Leistung:
+6.86%
6M Leistung:
-33.99%
1J Leistung:
-34.61%
1-Tages-Spanne:
$22.09
$23.18
1-Wochen-Bereich:
$22.09
$24.03
52-Wochen-Spanne:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Vergleichen Sie VERA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
22.29 | 1.48B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What drives Vera Therapeutics Inc. stock priceRapidly growing investment returns - Autocar Professional
Is Vera Therapeutics Inc. a good long term investmentBreakthrough profit margins - jammulinksnews.com
What analysts say about Vera Therapeutics Inc. stockConsistently high yield - jammulinksnews.com
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Fund Remains in Vera Therapeutics Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy - MSN
how vera therapeutics inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
How Vera Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Vera Therapeutics Inc. stock price move sharplyFree Stock Market Forums - Newser
Why Vera Therapeutics Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans - MSN
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 200K+ Shares in Stock Options and RSUs for New Hires - Stock Titan
Polycythemia Vera Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
How to Take Advantage of moves in (VERA) - news.stocktradersdaily.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Vera Therapeutics (VERA): Insider Buying and Clinical Breakthroughs Signal a Golden Opportunity - AInvest
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Vera Therapeutics director Enright buys shares worth $5.2m By Investing.com - Investing.com UK
Vera Therapeutics director Enright buys shares worth $5.2m - Investing.com
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):